• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $AVTR

    Avantor Inc.

    Subscribe to $AVTR
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Avantor, Inc. provides products and services to customers in biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, and clinical trial kits. It also provides equipment and instrumentation products, including filtration systems, virus inactivation systems, incubators, analytical instruments, evaporators, ultra-low-temperature freezers, biological safety cabinets, and critical environment supplies. In addition, the company offers services and specialty procurements comprising onsite lab and production, clinical, equipment, procurement and sourcing, and biopharmaceutical material scale-up and development services. Avantor, Inc. was founded in 1904 and is headquartered in Radnor, Pennsylvania.

    IPO Year: 2019

    Exchange: NYSE

    Website: avantorsciences.com

    Recent Analyst Ratings for Avantor Inc.

    DatePrice TargetRatingAnalyst
    8/1/2025Buy → Hold
    Jefferies
    4/29/2025$14.00Buy → Neutral
    Goldman
    4/28/2025$15.50Buy → Hold
    TD Cowen
    4/28/2025$14.00Buy → Hold
    Stifel
    4/28/2025Overweight → Equal-Weight
    Morgan Stanley
    1/17/2025$29.00 → $25.00Buy → Neutral
    UBS
    8/28/2024$30.00Overweight
    Wells Fargo
    7/10/2024$30.00 → $23.00Buy → Neutral
    Citigroup
    1/4/2024$19.50 → $26.00In-line → Outperform
    Evercore ISI
    12/11/2023$21.00 → $28.00Market Perform → Outperform
    TD Cowen
    See more ratings

    Avantor Inc. Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Avantor downgraded by Jefferies

    Jefferies downgraded Avantor from Buy to Hold

    8/1/25 1:45:47 PM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Avantor downgraded by Goldman with a new price target

    Goldman downgraded Avantor from Buy to Neutral and set a new price target of $14.00

    4/29/25 8:05:35 AM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Avantor downgraded by TD Cowen with a new price target

    TD Cowen downgraded Avantor from Buy to Hold and set a new price target of $15.50

    4/28/25 8:32:10 AM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Avantor downgraded by Stifel with a new price target

    Stifel downgraded Avantor from Buy to Hold and set a new price target of $14.00

    4/28/25 8:31:49 AM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Avantor downgraded by Morgan Stanley

    Morgan Stanley downgraded Avantor from Overweight to Equal-Weight

    4/28/25 8:31:44 AM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Avantor downgraded by UBS with a new price target

    UBS downgraded Avantor from Buy to Neutral and set a new price target of $25.00 from $29.00 previously

    1/17/25 7:28:22 AM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Wells Fargo initiated coverage on Avantor with a new price target

    Wells Fargo initiated coverage of Avantor with a rating of Overweight and set a new price target of $30.00

    8/28/24 7:34:12 AM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Avantor downgraded by Citigroup with a new price target

    Citigroup downgraded Avantor from Buy to Neutral and set a new price target of $23.00 from $30.00 previously

    7/10/24 7:23:30 AM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Avantor upgraded by Evercore ISI with a new price target

    Evercore ISI upgraded Avantor from In-line to Outperform and set a new price target of $26.00 from $19.50 previously

    1/4/24 8:00:57 AM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Avantor upgraded by TD Cowen with a new price target

    TD Cowen upgraded Avantor from Market Perform to Outperform and set a new price target of $28.00 from $21.00 previously

    12/11/23 7:12:48 AM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Avantor Inc. Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP, Chief HR Officer Hankamer Brittany covered exercise/tax liability with 181 shares, decreasing direct ownership by 0.11% to 171,563 units (SEC Form 4)

    4 - Avantor, Inc. (0001722482) (Issuer)

    8/15/25 4:35:16 PM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    EVP, AMEA Couturier Christophe was granted 65,217 shares, increasing direct ownership by 45% to 211,271 units (SEC Form 4)

    4 - Avantor, Inc. (0001722482) (Issuer)

    8/12/25 5:04:18 PM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SVP & Chief Accounting Officer Eck Steven W sold $39,592 worth of shares (3,476 units at $11.39), decreasing direct ownership by 6% to 55,068 units (SEC Form 4)

    4 - Avantor, Inc. (0001722482) (Issuer)

    8/6/25 4:32:53 PM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SVP & Chief Accounting Officer Eck Steven W covered exercise/tax liability with 1,385 shares, decreasing direct ownership by 2% to 58,544 units (SEC Form 4)

    4 - Avantor, Inc. (0001722482) (Issuer)

    8/4/25 4:43:05 PM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    EVP, Chief Legal & Compliance Sokenu Claudius covered exercise/tax liability with 3,123 shares, decreasing direct ownership by 2% to 177,106 units (SEC Form 4)

    4 - Avantor, Inc. (0001722482) (Issuer)

    7/25/25 4:32:28 PM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    President Laboratory Solutions Walker Corey covered exercise/tax liability with 2,730 shares, decreasing direct ownership by 1% to 231,271 units (SEC Form 4)

    4 - Avantor, Inc. (0001722482) (Issuer)

    6/24/25 5:20:19 PM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Director Summe Gregory L bought $375,000 worth of shares (30,000 units at $12.50) (SEC Form 4)

    4 - Avantor, Inc. (0001722482) (Issuer)

    5/27/25 4:58:03 PM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Director Summe Gregory L bought $253,000 worth of shares (20,000 units at $12.65) (SEC Form 4)

    4 - Avantor, Inc. (0001722482) (Issuer)

    5/22/25 5:37:34 PM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    President & CEO Stubblefield Michael gifted 76,000 shares and received a gift of 76,000 shares, decreasing direct ownership by 6% to 1,219,013 units (SEC Form 4)

    4 - Avantor, Inc. (0001722482) (Issuer)

    5/21/25 5:37:32 PM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    President Laboratory Solutions Walker Corey was granted 162,866 shares, increasing direct ownership by 229% to 234,001 units (SEC Form 4)

    4 - Avantor, Inc. (0001722482) (Issuer)

    5/12/25 5:35:49 PM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Avantor Inc. Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Summe Gregory L bought $375,000 worth of shares (30,000 units at $12.50) (SEC Form 4)

    4 - Avantor, Inc. (0001722482) (Issuer)

    5/27/25 4:58:03 PM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Director Summe Gregory L bought $253,000 worth of shares (20,000 units at $12.65) (SEC Form 4)

    4 - Avantor, Inc. (0001722482) (Issuer)

    5/22/25 5:37:34 PM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Director Summe Gregory L bought $300,000 worth of shares (25,000 units at $12.00) (SEC Form 4)

    4 - Avantor, Inc. (0001722482) (Issuer)

    5/9/25 4:51:58 PM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Director Massaro Joseph R bought $99,630 worth of shares (8,100 units at $12.30), increasing direct ownership by 30% to 35,038 units (SEC Form 4)

    4 - Avantor, Inc. (0001722482) (Issuer)

    4/29/25 5:58:52 PM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Director Summe Gregory L bought $312,500 worth of shares (25,000 units at $12.50) (SEC Form 4)

    4 - Avantor, Inc. (0001722482) (Issuer)

    4/29/25 5:58:40 PM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Director Kang Lan bought $62,850 worth of shares (5,000 units at $12.57), increasing direct ownership by 17% to 35,215 units (SEC Form 4)

    4 - Avantor, Inc. (0001722482) (Issuer)

    4/29/25 5:58:29 PM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Director Peacock Jonathan M bought $103,646 worth of shares (8,091 units at $12.81), increasing direct ownership by 4% to 202,715 units (SEC Form 4)

    4 - Avantor, Inc. (0001722482) (Issuer)

    4/29/25 5:58:18 PM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Avantor Inc. SEC Filings

    View All

    Avantor Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - Avantor, Inc. (0001722482) (Filer)

    8/13/25 5:03:52 PM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Amendment: SEC Form SCHEDULE 13G/A filed by Avantor Inc.

    SCHEDULE 13G/A - Avantor, Inc. (0001722482) (Subject)

    8/13/25 4:58:00 PM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form 10-Q filed by Avantor Inc.

    10-Q - Avantor, Inc. (0001722482) (Filer)

    8/1/25 9:00:18 AM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Avantor Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Avantor, Inc. (0001722482) (Filer)

    8/1/25 6:13:38 AM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Avantor Inc. filed SEC Form 8-K: Regulation FD Disclosure

    8-K - Avantor, Inc. (0001722482) (Filer)

    7/21/25 5:02:21 PM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form SD filed by Avantor Inc.

    SD - Avantor, Inc. (0001722482) (Filer)

    5/30/25 4:37:48 PM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Avantor Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    8-K - Avantor, Inc. (0001722482) (Filer)

    5/12/25 5:16:45 PM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Avantor Inc. filed SEC Form 8-K: Leadership Update, Other Events, Financial Statements and Exhibits

    8-K - Avantor, Inc. (0001722482) (Filer)

    4/28/25 8:29:56 AM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form 10-Q filed by Avantor Inc.

    10-Q - Avantor, Inc. (0001722482) (Filer)

    4/25/25 9:00:12 AM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Avantor Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Avantor, Inc. (0001722482) (Filer)

    4/25/25 6:21:21 AM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Avantor Inc. Press Releases

    Fastest customizable press release news feed in the world

    View All

    Avantor® Reiterates Shareholder Value Creation Focus

    Emmanuel Ligner, Seasoned Leader with Proven Track Record of Value Creation in Life Sciences, to Begin Role as CEO Next Week RADNOR, Pa., Aug. 11, 2025 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, today issued the following statement in response to the letter issued by Engine Capital:  The Board of Directors is actively engaged in overseeing the setting and execution of the Company's strategy and is committed to always acting in the best inter

    8/11/25 9:33:00 AM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Engine Capital Sends Letter to Avantor's Board of Directors Regarding Opportunities to Improve Governance and Unlock Shareholder Value

    Believes Years of Self-Inflicted Issues Have Caused Avantor to Trade at a Meaningful Discount to its Intrinsic Value and Life Sciences Peers Contends the Board Has Failed to Remedy Operating Underperformance, Ineffective Cost Controls and Poor Capital Deployment – Resulting in Significant Value Destruction Over Every Relevant Period Makes Clear the Board Needs to Be Refreshed with New Directors with Successful Experience in Healthcare Distribution, Capital Allocation and Leadership at Relevant Companies Sees Path to Realizing 100% Upside in Share Price by End of 2027 by Prioritizing Cost Discipline, Operational Improvements, Portfolio Optimization and Immediate Share Repurchases Eng

    8/11/25 7:00:00 AM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Avantor® Reports Second Quarter 2025 Results

    Net sales of $1.68 billion, decrease of 1%; organic revenue was flatNet income of $65 million; Adjusted EBITDA of $280 millionDiluted GAAP EPS of $0.09; adjusted EPS of $0.24Operating cash flow of $154 million; free cash flow of $125 millionRADNOR, Pa., Aug. 1, 2025 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, today reported financial results for its second fiscal quarter ended June 30, 2025. "In the second quarter, we remained focused on driv

    8/1/25 6:05:00 AM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Avantor Announces Emmanuel Ligner as Next President and CEO

    Seasoned Executive with Proven Track Record of Value Creation in Life Sciences RADNOR, Pa., July 21, 2025 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, today announced that it has named Emmanuel Ligner, President and Chief Executive Officer, effective August 18, 2025. Mr. Ligner succeeds Michael Stubblefield, who will, as previously announced, step down from his role as Director, President and Chief Executive Officer upon Mr. Ligner's appointme

    7/21/25 7:05:00 AM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Avantor® to Host Second Quarter 2025 Earnings Call on Friday, August 1, 2025

    RADNOR, Pa., June 27, 2025 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, announced that it will release its second quarter 2025 financial results before the market opens on Friday, August 1, and will hold a conference call on the same day at 8:00 a.m. Eastern Time to discuss the results. To hear a live audio webcast of the session, visit Events & Presentations in the Investor section of Avantor's website, ir.avantorsciences.com. A replay of the

    6/27/25 8:05:00 AM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Avantor® to Participate in the 2025 RBC Capital Markets Global Healthcare Conference

    RADNOR, Pa., May 16, 2025 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, announced that Brent Jones, Executive Vice President and Chief Financial Officer, will be participating in a fireside chat at the RBC Capital Markets Global Healthcare Conference in New York on Tuesday, May 20, 2025 at approximately 8:00 a.m. Eastern Time.  To view the presentation slides and to hear a live audio webcast of the session, visit Events & Presentations in the I

    5/16/25 8:30:00 AM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Avantor® to Participate in Bank of America Securities 2025 Health Care Conference

    RADNOR, Pa., May 2, 2025 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, announced that Michael Stubblefield, President and CEO, will be participating in a fireside chat at the Bank of America Securities 2025 Health Care Conference in Las Vegas on Tuesday, May 13, 2025 at approximately 10:00 a.m. Pacific Time.  To hear a live audio webcast of the session, visit Events & Presentations in the Investor section of Avantor's website, ir.avantorscience

    5/2/25 8:05:00 AM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Avantor® Announces CEO Transition

    Board initiates search process to identify next CEO RADNOR, Pa., April 25, 2025 /PRNewswire/ -- Avantor, Inc., a leading global provider of mission-critical products and services for the life sciences and advanced technology industries, today announced that Michael Stubblefield intends to step down from his role as Director, President and Chief Executive Officer upon the appointment of a successor. The Board and Mr. Stubblefield agreed that now is the right time to initiate a leadership transition. The Board has initiated a search process to identify the Company's next CEO led

    4/25/25 6:07:00 AM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Avantor® Reports First Quarter 2025 Results

    Net sales of $1.58 billion, decrease of 6%; organic decline of 2%Net income of $64.5 million; Adjusted EBITDA of $269.5 millionDiluted GAAP EPS of $0.09; adjusted EPS of $0.23Operating cash flow of $109.3 million; free cash flow of $82.1 millionAnnounces significant actions across the business to accelerate growth and enhance cost structure; increasing cost transformation target to $400 million in gross run-rate savings exiting 2027RADNOR, Pa., April 25, 2025 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, today reported financial results for its first fiscal q

    4/25/25 6:05:00 AM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Avantor® Showcases Scalable Fluid Handling Innovations at INTERPHEX

    Industry leading set of technologies to drive scalability, flexibility, and efficiency in biologics production RADNOR, Pa., April 1, 2025 /PRNewswire/ -- Avantor®, Inc., a leading global provider of mission-critical products and services for the life sciences and advanced technology industries, announces its presence at INTERPHEX, the premier annual gathering of pharmaceutical, biotechnology, and device development and manufacturing professionals. The company will showcase fluid handling technologies that support every step of the bioprocessing continuum, delivering exceptional scalability, flexibility, and efficiency in media and buffer preparation, filtration, purification, and final form

    4/1/25 8:05:00 AM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Avantor Inc. Leadership Updates

    Live Leadership Updates

    View All

    Avantor® Appoints Dame Louise Makin, DBE, Ph.D., to its Board of Directors

    RADNOR, Pa., Nov. 6, 2024 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, announced that the Avantor Board of Directors has appointed Dame Louise Makin, DBE, Ph.D., as a director with an initial term expiring at Avantor's 2025 Annual Meeting of Stockholders. The appointment of Dame Louise as an independent director fills a vacant board seat. Dame Louise brings a wealth of leadership and industry experience to the Avantor Board. She served as Chief Executive Officer of BTG plc, an international specialist healthcare company, for 15 years and led their transform

    11/6/24 8:05:00 AM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Wheels Up Announces Gregory Summe to Join Board of Directors

    Veteran Leader Brings Deep Strategic, Aviation, and Governance Experience to Boardroom ATLANTA, Aug. 8, 2024 /PRNewswire/ -- Wheels Up Experience Inc. (NYSE:UP) today announced that Gregory L. Summe, Managing Partner of Glen Capital Partners LLC, joined its Board of Directors, effective August 7. Summe fills the unexpired term of David Adelman, who is stepping down to focus on other professional pursuits. Summe's initial term as a Class II director will continue until the 2026 annual meeting of the Company's stockholders. He will serve on the Audit and Compensation Committees

    8/8/24 8:05:00 AM ET
    $AVTR
    $GRAL
    $NXPI
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Medical Specialities
    Health Care

    Avantor Set to Join S&P MidCap 400; QuidelOrtho & Schneider National to Join S&P SmallCap 600

    NEW YORK, July 23, 2024 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P MidCap 400 and S&P SmallCap 600: Avantor Inc. (NYSE:AVTR) will replace QuidelOrtho Corp. (NASD:QDEL) in the S&P MidCap 400, and QuidelOrtho will replace Hibbett Inc. (NASD:HIBB) in the S&P SmallCap 600 effective prior to the opening of trading on Friday, July 26. JD Sports Fashion Plc (XLON: JD) is acquiring Hibbett in a deal expected to close soon pending final closing conditions.Schneider National Inc. (NYSE:SNDR) will replace U.S. Silica Holdings Inc. (NYSE:SLCA) in the S&P SmallCap 600 effective prior to the opening of trading on Wednesday, July 31. Apollo Global Management Inc. (NYS

    7/23/24 7:17:00 PM ET
    $APO
    $AVTR
    $HIBB
    Investment Managers
    Finance
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Avantor® Appoints Corey Walker as President of Laboratory Solutions

    RADNOR, Pa. , June 21, 2024 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technologies industries, today announced that Corey Walker has rejoined the company as President of Avantor's Laboratory Solutions business, reporting to CEO Michael Stubblefield. "Corey's deep knowledge of our end markets and industry, coupled with his familiarity with our organization and customers, makes him the ideal leader for our Laboratory Solutions business," said Michael Stubblefield,

    6/21/24 7:47:00 AM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Avantor Inc. Financials

    Live finance-specific insights

    View All

    Avantor® Reports Second Quarter 2025 Results

    Net sales of $1.68 billion, decrease of 1%; organic revenue was flatNet income of $65 million; Adjusted EBITDA of $280 millionDiluted GAAP EPS of $0.09; adjusted EPS of $0.24Operating cash flow of $154 million; free cash flow of $125 millionRADNOR, Pa., Aug. 1, 2025 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, today reported financial results for its second fiscal quarter ended June 30, 2025. "In the second quarter, we remained focused on driv

    8/1/25 6:05:00 AM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Avantor Announces Emmanuel Ligner as Next President and CEO

    Seasoned Executive with Proven Track Record of Value Creation in Life Sciences RADNOR, Pa., July 21, 2025 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, today announced that it has named Emmanuel Ligner, President and Chief Executive Officer, effective August 18, 2025. Mr. Ligner succeeds Michael Stubblefield, who will, as previously announced, step down from his role as Director, President and Chief Executive Officer upon Mr. Ligner's appointme

    7/21/25 7:05:00 AM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Avantor® to Host Second Quarter 2025 Earnings Call on Friday, August 1, 2025

    RADNOR, Pa., June 27, 2025 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, announced that it will release its second quarter 2025 financial results before the market opens on Friday, August 1, and will hold a conference call on the same day at 8:00 a.m. Eastern Time to discuss the results. To hear a live audio webcast of the session, visit Events & Presentations in the Investor section of Avantor's website, ir.avantorsciences.com. A replay of the

    6/27/25 8:05:00 AM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Avantor® Announces CEO Transition

    Board initiates search process to identify next CEO RADNOR, Pa., April 25, 2025 /PRNewswire/ -- Avantor, Inc., a leading global provider of mission-critical products and services for the life sciences and advanced technology industries, today announced that Michael Stubblefield intends to step down from his role as Director, President and Chief Executive Officer upon the appointment of a successor. The Board and Mr. Stubblefield agreed that now is the right time to initiate a leadership transition. The Board has initiated a search process to identify the Company's next CEO led

    4/25/25 6:07:00 AM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Avantor® Reports First Quarter 2025 Results

    Net sales of $1.58 billion, decrease of 6%; organic decline of 2%Net income of $64.5 million; Adjusted EBITDA of $269.5 millionDiluted GAAP EPS of $0.09; adjusted EPS of $0.23Operating cash flow of $109.3 million; free cash flow of $82.1 millionAnnounces significant actions across the business to accelerate growth and enhance cost structure; increasing cost transformation target to $400 million in gross run-rate savings exiting 2027RADNOR, Pa., April 25, 2025 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, today reported financial results for its first fiscal q

    4/25/25 6:05:00 AM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Avantor® to Report First Quarter 2025 Earnings on Friday, April 25, 2025

    RADNOR, Pa., March 28, 2025 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, announced that it will release its first quarter 2025 financial results before the market opens on Friday, April 25, and will hold a conference call to discuss the results on the same day at 8:00 a.m. Eastern Daylight Time. To hear a live audio webcast of the session, visit Events & Presentations in the Investor section of Avantor's website, ir.avantorsciences.com. A repl

    3/28/25 8:05:00 AM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Avantor® Reports Fourth Quarter and Full Year 2024 Results

    Fourth Quarter 2024 Net sales of $1.69 billion, decrease of 2%; organic growth of 1%Net income of $500.4 million; Adjusted EBITDA of $307.7 millionDiluted GAAP EPS of $0.73; adjusted EPS of $0.27Operating cash flow of $173.3 million; free cash flow of $222.1 millionFull Year 2024 Net sales of $6.78 billion, decrease of 3%; organic decline of 2%Net income of $711.5 million; Adjusted EBITDA of $1,198.8 millionDiluted GAAP EPS of $1.04; adjusted EPS of $0.99Operating cash flow of $840.8 million; free cash flow of $768.3 millionRADNOR, Pa., Feb. 7, 2025 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences

    2/7/25 6:05:00 AM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Avantor® to Report Fourth Quarter and Full Year 2024 Earnings on Friday, February 7, 2025

    RADNOR, Pa., Jan. 10, 2025 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, announced that it will release its fourth quarter and full year 2024 financial results before the market opens on Friday, February 7, and will hold a conference call to discuss the results on the same day at 8:00 a.m. Eastern Standard Time. To hear a live audio webcast of the session, visit Events & Presentations in the Investor section of Avantor's website, ir.avantorscie

    1/10/25 8:05:00 AM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Avantor® Reports Third Quarter 2024 Results

    Net sales of $1.71 billion, decrease of 0.3%; organic decline of 0.7%Net income of $57.8 million; Adjusted EBITDA of $302.5 millionDiluted GAAP EPS of $0.08; adjusted EPS of $0.26Operating cash flow of $244.8 million; free cash flow of $204.0 millionRADNOR, Pa., Oct. 25, 2024 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, today reported financial results for its third fiscal quarter ended September 30, 2024. "Our team delivered another quarter o

    10/25/24 6:05:00 AM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Avantor® to Host Third Quarter 2024 Earnings Call on Friday, October 25, 2024

    RADNOR, Pa., Sept. 27, 2024 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, will release its third quarter 2024 financial results before the market opens on Friday, October 25, and will hold a conference call on the same day at 8:00 a.m. Eastern Time to discuss the results. To hear a live audio webcast of the session, visit Events & Presentations in the Investor section of Avantor's website, ir.avantorsciences.com. A replay of the webcast will be available for 30 days. About AvantorAvantor® is a leading life science tools company and global provider of mission

    9/27/24 8:05:00 AM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Avantor Inc. Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Avantor Inc.

    SC 13G/A - Avantor, Inc. (0001722482) (Subject)

    11/14/24 1:28:33 PM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Amendment: SEC Form SC 13G/A filed by Avantor Inc.

    SC 13G/A - Avantor, Inc. (0001722482) (Subject)

    8/9/24 3:22:24 PM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Amendment: SEC Form SC 13G/A filed by Avantor Inc.

    SC 13G/A - Avantor, Inc. (0001722482) (Subject)

    8/7/24 4:09:12 PM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Amendment: SEC Form SC 13G/A filed by Avantor Inc.

    SC 13G/A - Avantor, Inc. (0001722482) (Subject)

    7/10/24 2:17:07 PM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form SC 13G/A filed by Avantor Inc. (Amendment)

    SC 13G/A - Avantor, Inc. (0001722482) (Subject)

    2/16/24 4:29:43 PM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form SC 13G/A filed by Avantor Inc. (Amendment)

    SC 13G/A - Avantor, Inc. (0001722482) (Subject)

    2/14/24 10:04:39 AM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form SC 13G/A filed by Avantor Inc. (Amendment)

    SC 13G/A - Avantor, Inc. (0001722482) (Subject)

    2/14/24 10:03:03 AM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form SC 13G/A filed by Avantor Inc. (Amendment)

    SC 13G/A - Avantor, Inc. (0001722482) (Subject)

    2/13/24 4:58:57 PM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form SC 13G filed by Avantor Inc.

    SC 13G - Avantor, Inc. (0001722482) (Subject)

    2/13/24 1:10:58 PM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form SC 13G/A filed by Avantor Inc. (Amendment)

    SC 13G/A - Avantor, Inc. (0001722482) (Subject)

    2/12/24 12:12:58 PM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials